We also determined that the CET-CH-6 compound is particularly effective on the p53 mutation at amino acid residue 175 which is a clinically common hotspot mutation in GBM, and the most frequently mutated site at the DNA binding region [14]. Here, TP53 is linked to glioblastoma.